title: Molecular imaging of angiogenic therapy in peripheral vascular disease with alphanubeta3-integrin-targeted nanoparticles.
abstract: Noninvasive molecular imaging of angiogenesis could play a critical role in the clinical management of peripheral vascular disease patients. The alpha(nu)beta(3)-integrin, a well-established biomarker of neovascular proliferation, is an ideal target for molecular imaging of angiogenesis. This study investigates whether MR molecular imaging with alpha(nu)beta(3)-integrin-targeted perfluorocarbon nanoparticles can detect the neovascular response to angiogenic therapy. Hypercholesterolemic rabbits underwent femoral artery ligation followed by no treatment or angiogenic therapy with dietary L-arginine. MR molecular imaging performed 10 days after vessel ligation revealed increased signal enhancement in L-arginine-treated animals compared to controls. Furthermore, specifically targeted nanoparticles produced two times higher MRI signal enhancement compared to nontargeted particles, demonstrating improved identification of angiogenic vasculature with biomarker targeting. X-ray angiography performed 40 days postligation revealed that L-arginine treatment increased the development of collateral vessels. Histologic staining of muscle capillaries revealed a denser pattern of microvasculature in L-arginine-treated animals, confirming the MR and X-ray imaging results. The clinical application of noninvasive molecular imaging of angiogenesis could lead to earlier and more accurate detection of therapeutic response in peripheral vascular disease patients, enabling individualized optimization for a variety of treatment strategies.
authors.affiliation: Washington University, St. Louis, Missouri, USA. patrick@cmrl.wustl.edu
authors.forename: Patrick M
authors.initials: PM
authors.lastname: Winter
authors.forename: Shelton D
authors.initials: SD
authors.lastname: Caruthers
authors.forename: John S
authors.initials: JS
authors.lastname: Allen
authors.forename: Kejia
authors.initials: K
authors.lastname: Cai
authors.forename: Todd A
authors.initials: TA
authors.lastname: Williams
authors.forename: Gregory M
authors.initials: GM
authors.lastname: Lanza
authors.forename: Samuel A
authors.initials: SA
authors.lastname: Wickline
mesh_terms: D000284:Administration, Oral; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000818:Animals; D001120:Arginine / Q000008:administration & dosage*; D016503:Drug Delivery Systems / Q000379:methods; D039302:Integrin alphaVbeta3 / Q000032:analysis*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D015336:Molecular Probe Techniques; D053758:Nanoparticles; D058729:Peripheral Arterial Disease / Q000175:diagnosis* / Q000188:drug therapy*; D011379:Prognosis; D011817:Rabbits; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D039302:Integrin alphaVbeta3; D001120:Arginine